dHMN-AARS1

AARS1 | 2012

What Is dHMN-AARS1?

dHMN-AARS1 is a type of CMT caused by autosomal dominant mutations in the AARS1 gene. This gene provides instructions for making alanyl-tRNA synthetase, an enzyme that attaches the amino acid alanine to its transfer RNA during protein synthesis. Mutations in the AARS1 gene disrupt this function, leading to impaired nerve signal transmission.

dHMN-AARS1 is autosomal dominant, meaning that just one of the gene’s two copies needs a mutation to cause this subtype.

Clinical Features

The age of symptom onset in dHMN-AARS1 is variable, ranging from childhood to adulthood. As a motor neuropathy, dHMN-AARS1 primarily affects the most distal points, with weakness and atrophy of the feet and hands, and little to no involvement of the sensory nerves. Nerve conduction studies usually show somewhat slowed conduction velocities and reduced amplitudes, consistent with an axonal form of CMT.

dHMN-AARS1 symptoms may include:

  • Weakness and atrophy in the feet and lower legs
  • Foot drop
  • Reduced or absent reflexes
  • A steppage-style walking pattern
  • Foot deformities, including high arches, and hammertoes (clawed toes)
  • Progressive involvement of the hands
  • Difficulty with fine motor skills and manual dexterity
  • Additional symptoms not listed here

Disease Course

dHMN-AARS1 shows wide variability in severity and progression. Some individuals are mildly affected, while others develop a more severe disease. Disease progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
dHMN-AARS1

Classification
dHMN/HMN

Neuropathy Type
Axonal

Inheritance Pattern
autosomal dominant

Genetic Context

HGNC-Approved Gene Symbol
AARS1

Gene Full Name
alanyl-tRNA synthetase 1

HGNC Gene Alias(es)
AARS, ALARS

Chromosome
16q22.1

Zygosity of Responsible Variant
Heterozygous

Variant Mechanism

Dominant-Negative

Details

Confidence:
Medium

Prediction:
The literature predicts a dominant-negative mechanism for dHMN-AARS1: alanyl-tRNA synthetase works as a dimer, and the dominant AARS1 alleles yield a subunit that still assembles with its normal partner while failing to charge tRNA-Ala properly. Biallelic AARS1 loss instead causes an early-onset encephalopathy with hypomyelination, and the heterozygous parents in those families have no neuropathy, so one lost copy does not account for this dominant motor phenotype.

Rationale:
Halving AARS1 is tolerated, so the dominant alleles must do something a missing copy does not. Humanized yeast co-expression shows mutant AARS1 suppressing growth in the presence of the normal enzyme, and ablating the dimer interface relieves that suppression, which places the defect inside the shared dimer. Whether certain alleles instead acquire a novel binding partner remains argued across the dominant synthetase neuropathies, holding confidence at medium.

ClinVar Pathogenic Variants

View AARS1 ClinVar Variants

AARS1 OMIM Entry

AARS1 OMIM

More Info

dHMN-AARS1 Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

Alanyl-tRNA Synthetase Mutation in a Family with Dominant Distal Hereditary Motor Neuropathy

Authors

Zhao, Z., Hashiguchi, A., Hu, J., Sakiyama, Y., Okamoto, Y., Tokunaga, S., Zhu, L., Shen, H., & Takashima, H.

Publication Date
May 9, 2012

Updated: July 18, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


A Name That Does Too Much Work

Jean-Martin Charcot's name appears throughout medicine, but nowhere does it create more confusion than in the foot. Learn why the CMT foot and Charcot neuroarthropathy, also known as Charcot foot, share a name yet differ in how they develop, appear, and are managed.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.